The report analyzes and forecasts the natural killer cells therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global natural killer cells therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the natural killer cells therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of natural killer cells therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Key Players Insights
The global natural killer cells therapeutics market analysis provides insights regarding the highly competitive nature of the prominent players in the market and the various strategies adopted for garnering maximum share. These include expansion of their geographical presence through collaborations and focus on R&D activities for NK cells. Major players operating in the market include Affimed N.V., Celgene Corporation, Fate Therapeutics, Fortress Biotech, Glycostem Therapeutics BV, Innate Pharma S.A., Nantkwest Inc., Nkarta Therapeutics, Inc., NKT Therapeutics Inc., and Ziopharm Oncology Inc.
Segmentation:
By End User
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Section 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Section 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of cancer across the globe
3.5.1.2. Increase in government expenditure on healthcare
3.5.1.3. Surge in awareness regarding immunotherapy
3.5.2. Restraints
3.5.2.1. High cost of cancer immunotherapy treatment
3.5.2.2. Stringent government regulations toward approval of immunotherapy
3.5.3. Opportunity
3.5.3.1. Surge in R&D activities toward the development of immunotherapy
3.6. Government regulatory scenerio
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.6.4. Thailand
3.6.5. Singapore
3.6.6. Malaysia
3.6.7. Mexico
3.6.8. Australia
Section 4: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS
4.1. Overview
4.1.1. Market and forecast
4.2. Natural killer cell therapies
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.3.1. CNDO-109
4.2.3.2. oNKord
4.2.3.3. Natural Killer Cells
4.2.3.4. Others
4.3. NK cell-directed antibodies
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.3.1. MOGAMULIZUMAB
4.3.3.2. Lirilumab
4.3.3.3. AFM13
4.3.3.4. NKTT 120
4.3.3.5. Others
Section 5: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by region
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gastrointestinal diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Immunoproliferative disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
Section 6: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market and forecast
6.2. Research centers and institutes
6.2.1. Market and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospitals and clinics
6.3.1. Market and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market and forecast, by region
6.4.2. Market analysis, by country
Section 7: NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by therapeutics
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by therapeutics
7.2.5.2. U.S. market size and forecast, by application
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by therapeutics
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by therapeutics
7.2.5.8. Mexico market size and forecast, by application
7.2.5.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by therapeutics
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. UK market size and forecast, by therapeutics
7.3.5.2. UK market size and forecast, by application
7.3.5.3. UK market size and forecast, by end user
7.3.5.4. Germany market size and forecast, by therapeutics
7.3.5.5. Germany market size and forecast, by application
7.3.5.6. Germany market size and forecast, by end user
7.3.5.7. France market size and forecast, by therapeutics
7.3.5.8. France market size and forecast, by application
7.3.5.9. France market size and forecast, by end user
7.3.5.10. Italy market size and forecast, by therapeutics
7.3.5.11. Italy market size and forecast, by application
7.3.5.12. Italy market size and forecast, by end user
7.3.5.13. Spain market size and forecast, by therapeutics
7.3.5.14. Spain market size and forecast, by application
7.3.5.15. Spain market size and forecast, by end user
7.3.5.16. Rest of Europe market size and forecast, by therapeutics
7.3.5.17. Rest of Europe market size and forecast, by application
7.3.5.18. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by therapeutics
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan market size and forecast, by therapeutics
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by end user
7.4.5.4. China market size and forecast, by therapeutics
7.4.5.5. China market size and forecast, by application
7.4.5.6. China market size and forecast, by end user
7.4.5.7. Australia market size and forecast, by therapeutics
7.4.5.8. Australia market size and forecast, by application
7.4.5.9. Australia market size and forecast, by end user
7.4.5.10. India market size and forecast, by therapeutics
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.5.14. Rest of Asia-Pacific market size and forecast, by application
7.4.5.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by therapeutics
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by therapeutics
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. Saudi Arabia market size and forecast, by therapeutics
7.5.5.5. Saudi Arabia market size and forecast, by application
7.5.5.6. Saudi Arabia market size and forecast, by end user
7.5.5.7. South Africa market size and forecast, by therapeutics
7.5.5.8. South Africa market size and forecast, by application
7.5.5.9. South Africa market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by therapeutics
7.5.5.11. Rest of LAMEA market size and forecast, by application
7.5.5.12. Rest of LAMEA market size and forecast, by end user
Section 8: COMPANY PROFILES
8.1. AFFIMED N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CELGENE CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. FATE THERAPEUTICS INC.
8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Product portfolio
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. FORTRESS BIOTECH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. GLYCOSTEM THERAPEUTICS BV
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. INNATE PHARMA SA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NANTKWEST INC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. NKARTA THERAPEUTICS, INC.
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Product portfolio
8.8.4. Key strategic moves and developments
8.9. NKT THERAPEUTICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. ZIOPHARM ONCOLOGY INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers